Table of contents

  • Brand Names
  • Drug Combinations
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Unlabeled Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Genes that may be involved
  • Drug Interactions
  • Nutrition/Nutraceutical Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names


Belgium: Paronal; Czech Republic: Kidrolase; Estonia: Asparaginase; France: Kidrolase; Germany: Asparaginase; Greece: Asparaginase; Lithuania: Asparaginase; Malta: Asparaginase; Netherlands: Paronal; Poland: Asparaginase, Kidrolase; Romania: Asparaginase; Slovakia: Asparaginase.

North America

Canada: Kidrolase; USA: Elspar.

Latin America

Argentina: Kidrolase, Asparaginasa; Brazil: Elspar; Mexico: Elspar, Leunase.


Japan: Leunase.

Drug combinations

Asparaginase and Tryptophan


Asparaginase: Enzyme isolated from Escherichia coli, or obtained from other sources. L-Asparagine amidohydrolase. CAS-9015-68-3 (1970).

Pharmacologic Category

Other Antineoplastic Agents. Enzymes. (ATC-Code: L01XX02).

Mechanism of action

Inhibits protein synthesis by hydrolyzing asparagine to aspartic acid and ammonia.

Therapeutic use

Treatment of acute lymphocytic leukemia.

Pregnancy and lactiation implications

Use during pregnancy only if clearly needed. Not recommended during lactation.

Unlabeled use

Treatment of lymphoma.


Serious allergic reaction to asparaginase or any E. coli-derived asparaginase. Serious thrombosis with prior asparaginase treatment. Pancreatitis with prior asparaginase treatment. Serious hemorrhagic events with prior asparaginase treatment.

Warnings and precautions

Hazardous agent. Severe allergic reactions may occur. Use with caution in underlying coagulopathy (increased prothrombin time, partial thromboplastin time, hypofibrinogenemia, and cerebrovascular hemorrhage may occur). May cause hyperglycemia/glucose intolerance. Risk of pancreatitis. Thrombosis events (including sagittal sinus thrombosis) may occur. Possible tumor lysis syndrome and subsequent hyperuricemia and uric acid nephropathy. Use with caution in pre-existing hepatic impairment.



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart